62653-26-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-3,3-diphenyl-propionic acid is used as a building block in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows it to be incorporated into various drug molecules, enhancing their efficacy and selectivity.
Used in Organic Synthesis:
In the field of organic synthesis, 2-amino-3,3-diphenyl-propionic acid serves as a versatile intermediate. It is utilized in the preparation of a wide range of organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals, due to its reactive amino and carboxylic acid functional groups.
Used as an Enzyme Inhibitor:
2-Amino-3,3-diphenyl-propionic acid has been studied for its potential role as an inhibitor of dipeptidyl peptidase-IV (DPP-IV), an enzyme involved in the regulation of blood sugar levels. By inhibiting DPP-IV, it may help in the management of type 2 diabetes and related metabolic disorders.
Used in Antiparasitic Applications:
2-AMINO-3,3-DIPHENYL-PROPIONIC ACID has also been investigated for its antiparasitic properties. It may be used as a potential treatment for various parasitic infections, offering a new avenue for the development of antiparasitic drugs.
Used in Antimicrobial Applications:
Furthermore, 2-amino-3,3-diphenyl-propionic acid has shown promise in its antimicrobial activity. It can be employed as an antimicrobial agent in various applications, such as in the development of new antibiotics or as a preservative in different industries.

InChI:InChI=1/C15H15NO2/c16-14(15(17)18)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13-14H,16H2,(H,17,18)

Upstream product

• 947-91-1 Diphenylacetaldehyde 
• 270078-91-6 5-(diphenylmethyl)imidazolidine-2,4-dione 
• 10034-85-2 hydrogen iodide 
• 108-24-7 acetic anhydride 

Downstream Products

• 3963-62-0 2,2-Diphenylethylamine 
• 149597-92-2 (S)-β,β-diphenyl-α-alanine 
• 149597-91-1 (2R)-3,3-diphenylalanine 
• 189567-25-7 3,3-Diphenyl-2-(4,6-dimethyl-2-pyrimidinylamino)propionic acid 
• 107202-40-4 (R,S)-2-(t-boc-amino)-3,3-dicyclohexylpropan-1-ol 
• 107202-37-9 (1-hydroxymethyl-2,2-diphenyl-ethyl)-carbamic acid tert-butyl ester 
• 839719-72-1 2-(9H-fluoren-9-ylmethoxycarbonylamino)-3,3-diphenyl-propionic acid 
• 93406-82-7 ethyl 2-amino-3,3-diphenylpropanoate 
• 92646-33-8 2-amino-3,3-diphenyl-1-propanol 
• 189567-30-4 2-(3-Nitro-6-methoxy-2-pyridinylamino)-3,3-diphenylpropionic acid 

Relevant academic research and scientific papers

Immunomodulatory peptides

The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.

Bisoxazoline and bioxazoline chiral ligands bearing 4-diphenylmethyl shielding substituents. Diels-Alder reaction of cyclopentadiene with 3-acryloyl-2-oxazolidinone catalyzed by the aqua nickel(II) complex

Enantiopure 2-amino-3,3-diphenyl-1-propanol was synthesized by the hidantoin route starting from diphenyl-acetaldehyde followed by subsequent functional group transformations and optical resolution by a chiral HPLC. The amino alcohol can be converted into two new chiral ligands: 4,4'-bis(diphenylmethyl)-2,2'-bioxazoline and 2,2'-isopropylidenebis(4-diphenylmethyloxazoline), and further to complexes with copper(II) trifluoromethanesulfonate and nickel(II) perchlorate hexahydrate. The nickel(II) aqua complex obtained from the bisoxazoline effectively catalyzed the Diels-Alder reactions of cyclopentadiene with 3-acryloyl-2-oxazolidinone in high endo-selectivities and moderate enantioselectivities via a square planar transition structure.

Substituted quinoxaline-2-ones as glutamate receptor antagonists

A novel series of substituted quinoxaline 2-ones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

A process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines is described where N-protected DL-3,3-diphenylalanine or N-protected-DL-substituted 3,3-diphenylalanine are treated with (-)cinchonidine and the resulting salt resolved into the desired enantiomers, as well as derivatives thereof and valuable intermediates used in the process.

Hydrophobic peptides

Hydrophobic peptides having antihypertensive activity are disclosed. Also disclosed are pharmaceutical compositions comprising a hydrophobic peptide and a method of treatment of mammalian hypertension comprising administering a hydrophobic peptide to a hy